跳至主要内容
临床试验/NCT04042025
NCT04042025进行中(未招募)3 期

A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101

Novartis Gene Therapies31 个研究点 分布在 9 个国家目标入组 85 人开始时间: 2020年2月10日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
85
试验地点
31
主要终点
Number of Participants Who Experience a Clinically Significant Change From Baseline in Clinical Laboratory Assessments

研究概览

简要总结

This is a long-term follow-up safety and efficacy study of participants in clinical trials for spinal muscular atrophy (SMA) who were treated with onasemnogene abeparvovec-xioi. Participants will roll over from their respective previous (parent) study into this long-term study for continuous monitoring of safety as well as monitoring of continued efficacy and durability of response to onasemnogene abeparvovec-xioi treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Any participant with SMA who received onasemnogene abeparvovec-xioi gene replacement therapy in a Novartis Gene Therapies-sponsored clinical study
  • Participant/parent/legal guardian willing and able to complete the informed consent process and comply with study procedures and visit schedule

排除标准

  • Parent/legal guardian unable or unwilling to participate in the long-term follow-up safety study

研究组 & 干预措施

Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi

Other

Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene.

干预措施: Onasemnogene Abeparvovec-xioi (Biological)

结局指标

主要结局

Number of Participants Who Experience a Clinically Significant Change From Baseline in Clinical Laboratory Assessments

时间窗: Up to 5 years

Blood samples will be collected for hematology (including complete blood cell count) and chemistry.

Change From Baseline in Height Measurements

时间窗: Up to 5 years

Number of Participants Who Experience a Clinically Significant Change From Baseline in Pulmonary Assessment Results and Require Ventilatory Support

时间窗: Up to 15 years

Participants will receive pulmonary assessments by a pulmonologist or appropriate clinician. Respiratory device data will be reviewed for participants receiving non-invasive ventilatory support.

Number of Participants Who Experience a Clinically Significant Change From Baseline in Cardiac Assessments

时间窗: Up to 5 years

Cardiac assessments will include a 12-lead electrocardiogram, transthoracic echocardiogram and Troponin-I.

Number of Participants Who Reach Developmental Milestones

时间窗: Up to 5 years

Assessed via the developmental milestone checklist, formed of 10 yes/no questions. The developmental milestones are: head control, sitting with support, sitting without support, sitting without support for 30 seconds, hands-and-knees crawling, pulls to stand, standing with assistance, walking with assistance, standing alone and walking alone.

Number of Participants Who Experience Swallowing Dysfunction and Require Nutritional Support

时间窗: Up to 5 years

Assessed via the swallowing function questionnaire, formed of 4 yes/ no questions and 1 body weight question.

Number of Participants Who Experience a Clinically Significant Change From Baseline in Vital Signs Measurements

时间窗: Up to 5 years

Vital sign measurements will include blood pressure, respiratory rate, pulse, axillary temperature, and pulse oximetry.

Change From Baseline in Weight Measurements

时间窗: Up to 5 years

Number of Participants Who Experience at Least One Adverse Event of Special Interest (AESI)

时间窗: Up to 15 years

An AESI is defined as an AE occurring during any study phase that fulfills one of the following criteria: * Hepatotoxicity * Thrombotic microangiopathy * Cardiac adverse events * Dorsal root ganglia toxicity * New malignancies * New incidence of a neurologic disorder * New incidence of an autoimmune disorder * New incidence of hematologic disorder

Change From Baseline in Bayley Scales of Infant and Toddler Development

时间窗: Up to 42 months, 15 days of age

Third Edition (Bayley-III) to be performed in all patients up to 42 months, 15 days of age.

Change From Baseline in Revised Upper Limb Module (RULM) Score

时间窗: Up to 5 years

RULM score is based on a scale from 0 to 37 where lower scores reflect poorer upper limb functional ability.

Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score

时间窗: Up to 5 years

The HFMSE was devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE is formed of 33 assessments rated from 0 (unable to perform functional task) to 2 (able to perform functional task unassisted). Higher scores on the total scale of 0-66 indicates higher levels of motor ability.

Number of Participants Who Experience a Clinically Significant Change from Baseline in Physical Examination Findings

时间窗: Up to 5 years

The physical examination includes review of the following systems: head, ears, eyes, nose and throat, lungs/thorax, cardiovascular, abdomen, musculoskeletal, neurologic, dermatologic, lymphatic, and genitourinary. In addition, visual inspection of the spine, back, shoulders, and hips looking for spinal curvature and asymmetry will be carried out. Joints will be assessed for loss of mobility and contractures.

Change From Baseline in Assessment of Caregiver Experience With Neuromuscular Disease (ACEND)

时间窗: Up to 5 years

ACEND score is based on a scale from 1 to 41 where higher scores represent a better caregiver experience

Number of Participants With Other SMA Therapies Overall and by Type of Medications

时间窗: Year 6 to Year 15

Number of Participants With Concomitant Medications Overall and by Type of Medications

时间窗: Up to 5 years

Number of Participants Who Experience a Clinically Significant Change From Baseline in Observational Phase Questionnaire Results

时间窗: Year 6 to Year 15

The observational phase questionnaire includes 7 yes/no questions. Observation categories include: adverse events, hospitalizations, concomitant medications, ventilatory support and feeding support.

Change From Baseline in Clinical Evaluation of Language Fundamentals Fifth Edition (CELF-5) Performed in All Participants 5 to 21 Years of Age

时间窗: Up to 5 years

The CELF-5 Following Directions and Sentence Repetition subtests use scoring that varies based on age, but will be administered to participants 5-21 years of age. The Following Directions subtest will be scored from 0-33 with higher score being more advanced and the Recalling Sentences subtest will be scored from 0-78 with higher score being more advanced.

Number of Participants Who Experience at Least One Serious Adverse Event (SAE)

时间窗: Up to 15 years

An SAE is defined as any adverse event (appearance of \[or worsening of any pre existing\]) undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: * Fatal * Life-threatening * Results in persistent or significant disability/incapacity * Constitutes a congenital abnormality or birth defect * Requires in-patient hospitalization or prolongation of existing hospitalization * Is medically significant e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above

Change From Baseline in Cogstate Computerized Cognitive Battery Performed in Age 48 Months and Older

时间窗: Up to 5 years

The Cogstate Computerized Cognitive Battery consists of the Identification Test (scored 0 (best) to 1.5708 (worst)), the International Shopping List Test (scored 0 (worst) to 999 (best)), the International Shopping List Test-Delayed Recall (scored 0 (worst) to 999 (best)), the One Card Learning Test (scored 0 (worst) to 1.5708 (best)), and the One Back Test (scored 0 (worst) to 1.5708 (best)).

次要结局

未报告次要终点

研究者

发起方
Novartis Gene Therapies
申办方类型
Industry
责任方
Sponsor

研究点 (31)

Loading locations...

相似试验